Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis

Current Opinion in Investigational Drugs

Volumn 10, Issue 9, 2009, Pages 980-987

  Masson, D ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CYTOCHROME P450 3A4; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; KETOCONAZOLE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDAZOLAM; PLACEBO; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

AMBULATORY MONITORING; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; HEADACHE; HEART PROTECTION; HEMODYNAMICS; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; LIPOPROTEIN BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; MYALGIA; NONHUMAN; REVIEW; RHABDOMYOLYSIS; RHESUS MONKEY; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT FAILURE;

ANIMALS; AREA UNDER CURVE; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69549103369     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. 377215 A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H NATURE 2000 406 6792 203-207
2. 747846 In interests of patient safety, Pfizer stops all torcetrapib clinical trials; Company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer Inc PRESS RELEASE 2006 December 02
3. 836591 Merck's investigational CETP-inhibitor, MK-0859 (anacetrapib), produced positive effects on lipids with no observed blood pressure changes in phase IIb study. Merck & Co Inc PRESS RELEASE 2007 October 04
4. 853280 Effects of torcetrapib in patients at high risk for coronary events. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL et al N ENGL J MED 2007 357 21 2109-2122
5. 854847 CETP trials still inhibited as torcetrapib results fail to illuminate outcomes. Merck & Co Inc, Roche Holding AG, Pfizer Inc FDC REP PINK SHEET 2007 November 12 18-19
6. 898009 Roche continues solid sales growth in first quarter of 2008 - Both divisions significantly outpace their markets. Roche Holding AG PRESS RELEASE 2008 April 17
7. 900488 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M et al LANCET 2007 370 9603 1907-1914 •• Presents the results of two phase I clinical trials for anacetrapib in healthy volunteers, demonstrating that the drug efficiently increased HDL-C levels and did not affect blood pressure.
8. 933300 Company pipeline: Merck & Co. Merck & Co Inc COMPANY WORLD WIDE WEB SITE 2008 July 31
9. 933349 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E et al Br J PHARMACOL 2008 154 7 1465-1473 •• Provides evidence that hypertension and increases in aldosterone levels were independent of CETP inhibition by torcetrapib; also demonstrates that anacetrapib did not cause these side effects.
10. 942157 Lack of a clinically meaningful pharmacokinetic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Krishna R, Fallon M, Jin B, Keshavarz SS, Zajic S, Miksch D, Bieberdorf FA, Chodakewitz J, Wagner JA J CLIN PHARMACOL 2008 48 9 Abs 5
11. 942159 Assessment of the CYP3A4-mediated drug interaction potential of anacetrapib (ANA), a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Krishna R, Bergman AJ, Jin B, Garg A, Roadcap B, Clriou R, Dru J, Cote J, Laethem T, Vets E, Avery P et al J CLIN PHARMACOL 2008 48 9 Abs 30
12. 970989 Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN III, Van Dyck K, Hilliard D, Laterza O et al CLIN PHARMACOL THER 2008 84 6 679-683 • Clinical trial in healthy men provides key information on the kinetic and pharmacodynamic parameters of anacetrapib.
13. 974026 Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJP CIRCULATION 2008 118 24 2515-2522
14. 975737 Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. Krishna R, Bergman AJ, Jin B, Garg A, Roadcap B, Chiou R, Dru J, Cote J, Laethem T, Wang RW, Didolkar V et al J CLIN PHARMACOL 2009 49 1 80-87 • Demonstrates that anacetrapib did not interact significantly with other drugs metabolized through the CYP3a4 metabolic pathway.
15. 988588 Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW III, Sisk CM, Mitchel Y, Pasternak RC AM HEART J 2009 157 2 352-360 •• Presents the results from a phase II clinical trial of anacetrapib. Patients (n = 589) with primary hypercholesterolemia or mixed hyperlipidemia received anacetrapib or placebo, alone or in combination with atorvastatin. Anacetrapib efficiently increased HDL-C levels and decreased LDL-C levels without any associated side effects; the combination of anacetrapib and atorvastin enhanced the HDL-C-increasing and LDL-C-lowering effects of each compound.
16. 1000454 Model-based development of anacetrapib, a nove CETP inhibitor. Bergman A, Dykstra K, Jin B, Bloomfield D, Hartford A, Fallon M, Stone J, Wagner J, Krishna R CLIN PHARMACOL THER 2009 85 Suppl 1 PI-60
17. 1006489 Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, Wagner JA Br J CLIN PHARMACOL 2009 67 5 520-526
18. 1018190 NCT00685776: Study to assess the tolerability and efficacy of anacetrapib in patients with coronary heart disease (CHD) or CHD risk-equivalent disease. Merck & Co Inc CLINICALTRIALS. gOV 2009
19. 1018779 Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB JAMA-J AM MED ASSOC 1986 256 20 2835-2838
20. 1018784 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin AE N ENGL J MED 2004 350 15 1495-1504
21. 1018787 HDL as a target in the treatment of atherosclerotic cardiovascular disease. Linsel-Nitschke P, Tall AR NAT REV DRUG DISCOV 2005 4 3 193-205
22. 1018793 High-density lipoprotein as a therapeutic target: A systematic review. Singh IM, Shishehbor MH, Ansell BJ JAMA-J AM MED ASSOC 2007 298 7 786-798 • a systematic review highlighting that evidence supporting the concept of aggressively increasing HdL levels to prevent atherosclerosis is limited.
23. 1018798 The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. Masson D, Jiang XC, Lagrost L, Tall AR J LIPID RES 2009 50 Suppl S S201-S206
24. 1018803 Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR N ENGL J MED 1990 323 18 1234-1238
25. 1018804 Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R et al NATURE 1989 342 6248 448-451
26. 1018806 Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis. Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR ARTERIOSCLER THROMB VASC BIOL 2003 23 2 160-167
27. 1018820 Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME et al ARTERIOSCLER THROMB VASC BIOL 2004 24 3 490-497
28. 1018839 Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis. Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE CIRCULATION 2008 118 24 2506-2514 •• describes a clinical trial in which the data obtained suggested that high levels of HdL achieved via the inhibition of CETP could reduce atheroma volume. These results are therefore important to the future development and potential use of CETP inhibitors.
29. 1018841 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJP CIRCULATION 2002 105 18 2159-2165
30. 1019077 Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor. O'Neill E, Sparrow CP, Chen Y, Eveland B, Frantz-Wattley B, Milot D, Sinclair PJ, Ali A, Lu Z, Smith CJ, Taylor G et al J CLIN LIPIDOL 2007 1 5 Abs 126 •• One of the few available references that describes the characterization and preclinical development of anacetrapib.
31. 1020162 Pharmacokinetics and pharmacodynamics of single doses of MK-0859, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Bergman AJ, Jingjing C, Cote J, Van Hoydonck P, Chavez-Eng C, Lutz R, Laethem T, Van Dyck K, Hilliard D, Laterza O, Snyder C et al J CLIN LIPIDOL 2007 1 5 Abs 335
32. 1023394 Cardiovascular diseases - Fact sheet no 317. World Health Organization INTERNET SITE 2007 February 28
33. 1023407 Reducing morbidity and mortality in high risk patients with statins. Singh V, Deedwania P VASC HEALTH RISK MANAG 2009 5 2 495-507
34. 1023875 High density lipoprotein - An evolving target of therapy in the management of cardiovascular disease. Kapur NK, Ashen D, Blumenthal RS VASC HEALTH RISK MANAG 2008 4 1 39-57
35. 1024024 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr JAMA-J AM MED ASSOC 1998 279 20 1615-1622
36. 1025048 Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. Blasi E, Bamberger M, Knight D, Engwall M, Wolk R, Winter S, Betts A, John-Baptiste A, Keiser J J CARDIOVASC PHARMACOL 2009 53 6 507-516